Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy

References

Page 1

	Year	Citations
Ranibizumab for Neovascular Age-Related Macular Degeneration Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier, New England Journal of Medicine	2006	5.8K
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer Scott Antonia, Augusto Villegas, Davey B. Daniel, New England Journal of Medicine	2017	4.4K
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, New England Journal of Medicine	2018	3.7K
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis Marta Pàez‐Ribes, Elizabeth Allen, James Hudock, Cancer Cell Distant MetastasisMalignant DiseaseMedicinePathologyLocal Invasion	2009	2.3K
Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet Patricia E. Bunney, Anastasia N. Zink, Anja Holm, Physiology & Behavior ObesityMetabolic SyndromeNutritionEnergy MetabolismBody Composition	2017	2.1K
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy Yuhui Huang, Jian‐Ping Yuan, Elda Righi, Proceedings of the National Academy of Sciences	2012	1K
Isolating and engineering human antibodies using yeast surface display Ginger Chao, Wai Leung Lau, Benjamin J. Hackel, Nature Protocols EngineeringBiotechnologySynthetic BiologyProtein EngineeringAntibody Engineering	2006	937
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Journal of Clinical Oncology	2017	580
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study David F. McDermott, Jeffrey A. Sosman, Mario Sznol, Journal of Clinical Oncology	2016	554
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects Kannan Gunasekaran, Martin Pentony, Min Shen, Journal of Biological Chemistry EngineeringImmunoengineeringFc Heterodimer FormationElectrostatic Steering EffectsSynthetic Biology	2010	279

Page 1